Epigenetics: Concepts and relevance to IBD pathogenesis

Inflammatory Bowel Diseases

Volumn 18, Issue 10, 2012, Pages 1982-1996

  Scarpa, Melania ^a,b   Stylianou, Eleni ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Chromatin; Epigenetics; Gene transcription; Inflammation; Inflammatory bowel disease

Indexed keywords

DNA METHYLTRANSFERASE INHIBITOR; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE; UNTRANSLATED RNA;

ANTIINFLAMMATORY ACTIVITY; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL LINEAGE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CHRONIC INFLAMMATION; COLON CANCER; CROHN DISEASE; DEACETYLATION; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; ENVIRONMENTAL CHANGE; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC REGULATION; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; IMMUNE RESPONSE; INTESTINAL FIBROSIS; INTESTINE FLORA; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SUMOYLATION; TRANSCRIPTION INITIATION; UBIQUITINATION; ULCERATIVE COLITIS;

EPIGENESIS, GENETIC; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84866367184     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22934     Document Type: Review

References (139)

1. Kaser A, Zeissig S, Blumberg RS,. Inflammatory bowel disease. Annu Rev Immunol. 2010; 28: 573-621.
2. Danese S, Fiocchi C,. Ulcerative colitis. N Engl J Med. 2011; 365: 1713-1725.
3. Strober W, Fuss I, Mannon P,. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007; 117: 514-521. (Pubitemid 46348505)
4. Winter SE, Keestra AM, Tsolis RM, et al. The blessings and curses of intestinal inflammation. Cell Host Microbe. 2010; 8: 36-43.
5. Khor B, Gardet A, Xavier RJ,. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011; 474: 307-317.
6. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994; 180: 2359-2364. (Pubitemid 24351619)
7. Portela A, Esteller M,. Epigenetic modifications and human disease. Nat Biotechnol. 2010; 28: 1057-1068.
8. Bonasio R, Tu S, Reinberg D,. Molecular signals of epigenetic states. Science. 2010; 330: 612-616.
9. Petronis A,. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. Nature. 2010; 465: 721-727.
10. Margueron R, Reinberg D,. Chromatin structure and the inheritance of epigenetic information. Nat Rev Genet. 2010; 11: 285-296.
11. Gardner KE, Allis CD, Strahl BD,. Operating on chromatin, a colorful language where context matters. J Mol Biol. 2011; 409: 36-46.
12. Henikoff S, Shilatifard A,. Histone modification: cause or cog? Trends Genet. 2011; 27: 389-396.
13. Kouzarides T,. Chromatin modifications and their function. Cell. 2007; 128: 693-705. (Pubitemid 46273577)
14. Talbert PB, Henikoff S,. Histone variants-ancient wrap artists of the epigenome. Nat Rev Mol Cell Biol. 2010; 11: 264-275.
15. Ruthenburg AJ, Li H, Patel DJ, et al. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol. 2007; 8: 983-994. (Pubitemid 350174643)
16. Tan M, Luo H, Lee S, et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell. 2011; 146: 1016-1028.
17. Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007; 129: 823-837. (Pubitemid 46802390)
18. Wang Z, Zang C, Rosenfeld JA, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008; 40: 897-903. (Pubitemid 351913645)
19. Shahbazian MD, Grunstein M,. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem. 2007; 76: 75-100.
20. Yang XJ, Seto E,. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell. 2008; 31: 449-461.
21. Selvi BR, Mohankrishna DV, Ostwal YB, et al. Small molecule modulators of histone acetylation and methylation: a disease perspective. Biochim Biophys Acta. 2010; 1799: 810-828.
22. Roth SY, Denu JM, Allis CD,. Histone acetyltransferases. Annu Rev Biochem. 2001; 70: 81-120. (Pubitemid 32662206)
23. Shakespear MR, Halili MA, Irvine KM, et al. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 2011; 32: 335-343.
24. Copeland RA, Solomon ME, Richon VM,. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009; 8: 724-732.
25. Dillon SC, Zhang X, Trievel RC, et al. The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol. 2005; 6: 227.
26. Pedersen MT, Helin K,. Histone demethylases in development and disease. Trends Cell Biol. 2010; 20: 662-671.
27. Di Lorenzo A, Bedford MT,. Histone arginine methylation. FEBS Lett. 2011; 585: 2024-2031.
28. Baek SH,. When signaling kinases meet histones and histone modifiers in the nucleus. Mol Cell. 2011; 42: 274-284.
29. Gehani SS, Agrawal-Singh S, Dietrich N, et al. Polycomb group protein displacement and gene activation through MSK-dependent H3K27me3S28 phosphorylation. Mol Cell. 2010; 39: 886-900.
30. Weake VM, Workman JL,. Histone ubiquitination: triggering gene activity. Mol Cell. 2008; 29: 653-663. (Pubitemid 351400924)
31. Atanassov BS, Koutelou E, Dent SY,. The role of deubiquitinating enzymes in chromatin regulation. FEBS Lett. 2011; 585: 2016-2023.
32. Daniel JA, Torok MS, Sun ZW, et al. Deubiquitination of histone H2B by a yeast acetyltransferase complex regulates transcription. J Biol Chem. 2004; 279: 1867-1871. (Pubitemid 38084455)
33. Sun ZW, Allis CD,. Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. Nature. 2002; 418: 104-108. (Pubitemid 34742580)
34. Medzhitov R, Horng T,. Transcriptional control of the inflammatory response. Nat Rev Immunol. 2009; 9: 692-703.
35. Garcia-Dominguez M, Reyes JC,. SUMO association with repressor complexes, emerging routes for transcriptional control. Biochim Biophys Acta. 2009; 1789: 451-459.
36. Nathan D, Ingvarsdottir K, Sterner DE, et al. Histone sumoylation is a negative regulator in Saccharomyces cerevisiae and shows dynamic interplay with positive-acting histone modifications. Genes Dev. 2006; 20: 966-976.
37. Saha A, Wittmeyer J, Cairns BR,. Chromatin remodeling through directional DNA translocation from an internal nucleosomal site. Nat Struct Mol Biol. 2005; 12: 747-755. (Pubitemid 43102285)
38. Erdel F, Krug J, Langst G, et al. Targeting chromatin remodelers: signals and search mechanisms. Biochim Biophys Acta. 2011; 1809: 497-508.
39. Arnaudo AM, Molden RC, Garcia BA,. Revealing histone variant induced changes via quantitative proteomics. Crit Rev Biochem Mol Biol. 2011; 46: 284-294.
40. Campos EI, Reinberg D,. Histones: annotating chromatin. Annu Rev Genet. 2009; 43: 559-599.
41. Denis H, Ndlovu MN, Fuks F,. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO Rep. 2011; 12: 647-656.
42. Yang X, Lay F, Han H, et al. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci. 2010; 31: 536-546.
43. Jeltsch A,. Molecular enzymology of mammalian DNA methyltransferases. Curr Top Microbiol Immunol. 2006; 301: 203-225. (Pubitemid 43022673)
44. Meissner A, Mikkelsen TS, Gu H, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature. 2008; 454: 766-770.
45. Hellman A, Chess A,. Gene body-specific methylation on the active X chromosome. Science. 2007; 315: 1141-1143. (Pubitemid 46328027)
46. Zilberman D, Gehring M, Tran RK, et al. Genome-wide analysis of Arabidopsis thaliana DNA methylation uncovers an interdependence between methylation and transcription. Nat Genet. 2007; 39: 61-69. (Pubitemid 46026502)
47. Kriaucionis S, Heintz N,. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009; 324: 929-930.
48. Branco MR, Ficz G, Reik W,. Uncovering the role of 5- hydroxymethylcytosine in the epigenome. Nat Rev Genet. 2012; 13: 7-13.
49. Esteller M,. Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12: 861-874.
50. O'Connell RM, Rao DS, Chaudhuri AA, et al. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol. 2010; 10: 111-122.
51. Zhao Q, Rank G, Tan YT, et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol Biol. 2009; 16: 304-311.
52. Foster SL, Medzhitov R,. Gene-specific control of the TLR-induced inflammatory response. Clin Immunol. 2009; 130: 7-15.
53. Smale ST,. Selective transcription in response to an inflammatory stimulus. Cell. 2010; 140: 833-844.
54. Smale ST,. Transcriptional regulation in the innate immune system. Curr Opin Immunol. 2011; 24: 1-7.
55. Fuda NJ, Ardehali MB, Lis JT,. Defining mechanisms that regulate RNA polymerase II transcription in vivo. Nature. 2009; 461: 186-192.
56. Buratowski S,. Progression through the RNA polymerase II CTD cycle. Mol Cell. 2009; 36: 541-546.
57. Agalioti T, Lomvardas S, Parekh B, et al. Ordered recruitment of chromatin modifying and general transcription factors to the IFN-beta promoter. Cell. 2000; 103: 667-678.
58. Lomvardas S, Thanos D,. Modifying gene expression programs by altering core promoter chromatin architecture. Cell. 2002; 110: 261-271. (Pubitemid 34876553)
59. Nikolajczyk B,. Regulation of cytokine transcription in the context of chromatin. Arch Immunol Ther Exp (Warsz). 2006; 54: 299-305. (Pubitemid 44627667)
60. Saccani S, Pantano S, Natoli G,. Two waves of nuclear factor kappaB recruitment to target promoters. J Exp Med. 2001; 193: 1351-1359. (Pubitemid 32565964)
61. Saccani S, Natoli G,. Dynamic changes in histone H3 Lys 9 methylation occurring at tightly regulated inducible inflammatory genes. Genes Dev. 2002; 16: 2219-2224. (Pubitemid 35013084)
62. Saccani S, Pantano S, Natoli G,. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol. 2002; 3: 69-75. (Pubitemid 34065620)
63. Ramirez-Carrozzi VR, Braas D, Bhatt DM, et al. A unifying model for the selective regulation of inducible transcription by CpG islands and nucleosome remodeling. Cell. 2009; 138: 114-128.
64. Hargreaves DC, Horng T, Medzhitov R,. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell. 2009; 138: 129-145.
65. Miao F, Gonzalo IG, Lanting L, et al. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem. 2004; 279: 18091-18097. (Pubitemid 38560579)
66. Ramirez-Carrozzi VR, Nazarian AA, Li CC, et al. Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling complexes during an inflammatory response. Genes Dev. 2006; 20: 282-296. (Pubitemid 43200283)
67. Ghisletti S, Huang W, Jepsen K, et al. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev. 2009; 23: 681-693.
68. De Santa F, Narang V, Yap ZH, et al. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J. 2009; 28: 3341-3352.
69. Hodge DR, Xiao W, Clausen PA, et al. Interleukin-6 regulation of the human DNA methyltransferase (HDNMT) gene in human erythroleukemia cells. J Biol Chem. 2001; 276: 39508-39511.
70. Biswas SK, Lopez-Collazo E,. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 2009; 30: 475-487.
71. Smythies LE, Sellers M, Clements RH, et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest. 2005; 115: 66-75. (Pubitemid 40385506)
72. Chan C, Li L, McCall CE, et al. Endotoxin tolerance disrupts chromatin remodeling and NF-kappaB transactivation at the IL-1beta promoter. J Immunol. 2005; 175: 461-468. (Pubitemid 40884350)
73. Chen X, El Gazzar M, Yoza BK, et al. The NF-kappaB factor RelB and histone H3 lysine methyltransferase G9a directly interact to generate epigenetic silencing in endotoxin tolerance. J Biol Chem. 2009; 284: 27857-27865.
74. El Gazzar M, Yoza BK, Hu JY, et al. Epigenetic silencing of tumor necrosis factor alpha during endotoxin tolerance. J Biol Chem. 2007; 282: 26857-26864. (Pubitemid 47501896)
75. El Gazzar M, Liu T, Yoza BK, et al. Dynamic and selective nucleosome repositioning during endotoxin tolerance. J Biol Chem. 2010; 285: 1259-1271.
76. El Gazzar M, Yoza BK, Chen X, et al. Chromatin-specific remodeling by HMGB1 and linker histone H1 silences proinflammatory genes during endotoxin tolerance. Mol Cell Biol. 2009; 29: 1959-1971.
77. Foster SL, Hargreaves DC, Medzhitov R,. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature. 2007; 447: 972-978. (Pubitemid 46975746)
78. Wilson CB, Rowell E, Sekimata M,. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol. 2009; 9: 91-105.
79. Janson PC, Winerdal ME, Winqvist O,. At the crossroads of T helper lineage commitment-Epigenetics points the way. Biochim Biophys Acta. 2009; 1790: 906-919.
80. Akimzhanov AM, Yang XO, Dong C,. Chromatin remodeling of interleukin-17 (IL-17)-IL-17F cytokine gene locus during inflammatory helper T cell differentiation. J Biol Chem. 2007; 282: 5969-5972. (Pubitemid 47100812)
81. Lal G, Bromberg JS,. Epigenetic mechanisms of regulation of Foxp3 expression. Blood. 2009; 114: 3727-3735.
82. Lal G, Zhang N, van der Touw W, et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol. 2009; 182: 259-273.
83. Vanden Berghe W, Ndlovu MN, Hoya-Arias R, et al. Keeping up NF-kappaB appearances: epigenetic control of immunity or inflammation-triggered epigenetics. Biochem Pharmacol. 2006; 72: 1114-1131. (Pubitemid 44465844)
84. Feinberg AP,. Phenotypic plasticity and the epigenetics of human disease. Nature. 2007; 447: 433-440. (Pubitemid 46816750)
85. Jones PA, Baylin SB,. The epigenomics of cancer. Cell. 2007; 128: 683-692. (Pubitemid 46273572)
86. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009; 41: 178-186.
87. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005; 37: 391-400.
88. Seligson DB, Horvath S, McBrian MA, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009; 174: 1619-1628.
89. Simon JA, Lange CA,. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008; 647: 21-29.
90. Chase A, Cross NC,. Aberrations of EZH2 in cancer. Clin Cancer Res. 2011; 17: 2613-2618.
91. Martinez-Garcia E, Licht JD,. Deregulation of H3K27 methylation in cancer. Nat Genet. 2010; 42: 100-101.
92. Muraoka M, Konishi M, Kikuchi-Yanoshita R, et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene. 1996; 12: 1565-1569. (Pubitemid 26132043)
93. Shaknovich R, Melnick A,. Epigenetics and B-cell lymphoma. Curr Opin Hematol. 2011; 18: 293-299.
94. Ayton PM, Cleary ML,. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 2001; 20: 5695-5707. (Pubitemid 32928107)
95. Grand F, Kulkarni S, Chase A, et al. Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia. Cancer Res. 1999; 59: 3870-3874. (Pubitemid 29393542)
96. Bochar DA, Wang L, Beniya H, et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell. 2000; 102: 257-265.
97. Wong AK, Shanahan F, Chen Y, et al. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res. 2000; 60: 6171-6177.
98. Lujambio A, Esteller M,. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle. 2007; 6: 1455-1459.
99. Farazi TA, Spitzer JI, Morozov P, et al. miRNAs in human cancer. J Pathol. 2011; 223: 102-115.
100. Kang GH, Lee HJ, Hwang KS, et al. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol. 2003; 163: 1551-1556. (Pubitemid 37175101)
101. Stenvinkel P, Karimi M, Johansson S, et al. Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease? J Intern Med. 2007; 261: 488-499. (Pubitemid 46587721)
102. Richardson B, Scheinbart L, Strahler J, et al. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 1990; 33: 1665-1673.
103. Javierre BM, Richardson B,. A new epigenetic challenge: systemic lupus erythematosus. Adv Exp Med Biol. 2011; 711: 117-136.
104. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005; 352: 1967-1976. (Pubitemid 40638367)
105. Cosio BG, Mann B, Ito K, et al. Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. Am J Respir Crit Care Med. 2004; 170: 141-147. (Pubitemid 38925159)
106. Issa JP, Ahuja N, Toyota M, et al. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001; 61: 3573-3577. (Pubitemid 32694963)
107. Chan AO, Rashid A,. CpG island methylation in precursors of gastrointestinal malignancies. Curr Mol Med. 2006; 6: 401-408. (Pubitemid 43834253)
108. Tahara T, Shibata T, Nakamura M, et al. Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). Clin Exp Med. 2009; 9: 125-130.
109. Tahara T, Shibata T, Nakamura M, et al. Effect of MDR1 gene promoter methylation in patients with ulcerative colitis. Int J Mol Med. 2009; 23: 521-527.
110. Lin Z, Hegarty JP, Cappel JA, et al. Identification of disease-associated DNA methylation in intestinal tissues from patients with inflammatory bowel disease. Clin Genet. 2011; 80: 59-67.
111. Nimmo ER, Prendergast JG, Aldhous MC, et al. Genome-wide methylation profiling in Crohn's disease identifies altered epigenetic regulation of key host defense mechanisms including the Th17 pathway. Inflamm Bowel Dis. 2011 [Epub ahead of print].
112. Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology. 2008; 135: 1624-1635 e24.
113. Niki T, Rombouts K, De Bleser P, et al. A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology. 1999; 29: 858-867. (Pubitemid 29109602)
114. Rombouts K, Niki T, Greenwel P, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res. 2002; 278: 184-197. (Pubitemid 35002103)
115. Rishikof DC, Ricupero DA, Liu H, et al. Phenylbutyrate decreases type I collagen production in human lung fibroblasts. J Cell Biochem. 2004; 91: 740-748.
116. Huber LC, Brock M, Hemmatazad H, et al. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum. 2007; 56: 1087-1093. (Pubitemid 46608633)
117. Wang Z, Chen C, Finger SN, et al. Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis? Eur Respir J. 2009; 34: 145-155.
118. Mannaerts I, Nuytten NR, Rogiers V, et al. Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology. 2010; 51: 603-614.
119. Iyer A, Fenning A, Lim J, et al. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol. 2010; 159: 1408-1417.
120. Bechtel W, McGoohan S, Zeisberg EM, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med. 2010; 16: 544-550.
121. Sanders YY, Pardo A, Selman M, et al. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2008; 39: 610-618.
122. Coward WR, Watts K, Feghali-Bostwick CA, et al. Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis. Mol Cell Biol. 2010; 30: 2874-2886.
123. Mann J, Chu DC, Maxwell A, et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology. 2010; 138: 705-714, 14 e1-4.
124. McDonald OG, Wu H, Timp W, et al. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol. 2011; 18: 867-874.
125. Cole PA,. Chemical probes for histone-modifying enzymes. Nat Chem Biol. 2008; 4: 590-597.
126. Rius M, Lyko F,. Epigenetic cancer therapy: rationales, targets and drugs. Oncogene. 2011 [Epub ahead of print].
127. Chung YL, Lee MY, Wang AJ, et al. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther. 2003; 8: 707-717.
128. Glauben R, Batra A, Fedke I, et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol. 2006; 176: 5015-5022.
129. Lin HS, Hu CY, Chan HY, et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol. 2007; 150: 862-872.
130. Nasu Y, Nishida K, Miyazawa S, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage. 2008; 16: 723-732.
131. Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2003; 100: 2041-2046. (Pubitemid 36254570)
132. Halili MA, Andrews MR, Sweet MJ, et al. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem. 2009; 9: 309-319.
133. Dinarello CA,. Anti-inflammatory agents: present and future. Cell. 2010; 140: 935-950.
134. Butzner JD, Parmar R, Bell CJ, et al. Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut. 1996; 38: 568-573. (Pubitemid 26111377)
135. Lawrance IC,. Topical agents for idiopathic distal colitis and proctitis. J Gastroenterol Hepatol. 2011; 26: 36-43.
136. Jones PA, Taylor SM,. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980; 20: 85-93. (Pubitemid 10117303)
137. Robertson KD, Ait-Si-Ali S, Yokochi T, et al. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet. 2000; 25: 338-342. (Pubitemid 30437325)
138. Fuks F, Burgers WA, Godin N, et al. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J. 2001; 20: 2536-2544. (Pubitemid 32452872)
139. Marmorstein R, Trievel RC,. Histone modifying enzymes: structures, mechanisms, and specificities. Biochim Biophys Acta. 2009; 1789: 58-68.